AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2141757
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g n-3 fatty acids
Trial: 2141757
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g n-3 fatty acids
Trial: 2141757
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g n-3 fatty acids
Trial: 465277
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) 12.5 mg and 25 mg
Trial: 465277
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HCT and metoprolol
Trial: 21899891
Drug: Kaltenborn manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaltenborn manual therapy
Trial: 19132974
Drug: Topical glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glucocorticoids (GC)
Trial: 16766330
Drug: Exomega milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exomega milk applied twice a day for 2 months
Trial: 14722203
Drug: Infliximab plus
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab plus MTX (3 mg/kg or 10 mg/kg every 4 or 8 weeks)
Trial: 9756005
Drug: Initial daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial daily administration of 6 million units of natural interferon-alpha subcutaneously for 2 weeks, then thrice a week for 22 weeks (Group A)
Trial: 9756005
Drug: Thrice a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice a week administration of 6 million units of natural interferon-alpha for 26 weeks (Group B)
Trial: 9756005
Drug: Initial daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial daily administration of interferon (Group A)
Trial: 9756005
Drug: Thrice a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice a week administration of interferon (Group B)
Trial: 9756005
Drug: Initial daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial daily administration of interferon (Group A) in patients with genotype 1b
Trial: 9756005
Drug: Thrice a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice a week administration of interferon (Group B) in patients with genotype 1b
Trial: 3145297
Drug: Vehicle (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (control treatment)
Trial: 30661697
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (PJ) 200 ml/day for 6 weeks
Trial: 29055956
Drug: Higher daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher daily salt intake (2.0 g/day higher compared with normal weight individuals) after multivariable adjustment, 95% CI, 1.2‐2.8 g/day, P < 0.001
Trial: 25315830
Drug: Quetiapine (386.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (386.3 mg/day)
Trial: 25315830
Drug: Risperidone (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (3.2 mg/day)
Trial: 21574968
Drug: Sugammadex 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 16 mg/kg (Study A)
Trial: 21574968
Drug: Sugammadex 2
RxNorm normalized name: sugammadex 200 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2 mg/kg (Study B)
Trial: 16965429
Drug: Methyl aminolaevulinate-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT) for actinic keratosis (AK)
Trial: 16965429
Drug: Methyl aminolaevulinate-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT) for nodular basal cell carcinoma (BCC)
Trial: 16965429
Drug: Methyl aminolaevulinate-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT) for superficial basal cell carcinoma (BCC)
Trial: 7879632
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (various intervention sequences)
Trial: 29998524
Drug: C1-inhibitor (C1-INH)
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-inhibitor (C1-INH) subcutaneous (SC) administration, 40 IU/kg twice weekly
Trial: 29998524
Drug: C1-inhibitor (C1-INH)
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-inhibitor (C1-INH) subcutaneous (SC) administration, 60 IU/kg twice weekly
Trial: 29998524
Drug: C1-inhibitor (C1-INH)
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-inhibitor (C1-INH) intravenous (IV) administration, 1000 IU
Trial: 26014092
Drug: Diclofenac patch
RxNorm normalized name: diclofenac Medicated Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac patch applied twice a day for 7 days
Trial: 26014092
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch applied twice a day for 7 days
Trial: 24596084
Drug: Tonsillectomy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonsillectomy combined with steroid pulses
Trial: 24596084
Drug: Steroid pulses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid pulses alone
Trial: 18215213
Drug: Topiramate 300
RxNorm normalized name: topiramate 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate 300 mg/d
Trial: 12365887
Drug: Ketoprofen administered
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen administered before surgery and regular doses after discharge for 72 hours
Trial: 12365887
Drug: Ketoprofen administered
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen administered at discharge
Trial: 12365887
Drug: Ketoprofen doses
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen doses after discharge
Trial: 8135325
Drug: 6.7 mmol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.7 mmol (167 mg) magnesium aspartate
Trial: 2572616
Drug: Azelastine hydrochloride,
RxNorm normalized name: Azelastine Hydrochloride, 0.05% ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine hydrochloride, 8.8 mg
Trial: 29098501
Drug: Intravenous carperitide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous carperitide (0.02 μg/kg/min) in addition to standard treatment
Trial: 29098501
Drug: Matching standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching standard treatment
Trial: 25336731
Drug: Inactivated A(H1N1)pdm09
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated A(H1N1)pdm09 vaccine
Trial: 19549426
Drug: Olopatadine 0.6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine 0.6% nasal spray (2 sprays/nostril b.i.d.)
Trial: 19549426
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 50 microg nasal spray (2 sprays/nostril q.d.)
Trial: 19549426
Drug: Olopatadine 0.6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine 0.6% nasal spray
Trial: 19549426
Drug: Olopatadine 0.6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine 0.6% nasal spray and Fluticasone propionate 50 microg nasal spray
Trial: 19549426
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 50 microg nasal spray
Trial: 14530982
Drug: Power training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Power training (twice a week for 15 weeks)
Trial: 8216567
Drug: naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen sodium 550 mg twice daily for 10 days
Trial: 29483043
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg/d)
Trial: 27936233
Drug: Lopinavir-ritonavir (LPV-rtv)
RxNorm normalized name: lopinavir / ritonavir
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lopinavir-ritonavir (LPV-rtv) based ART with anti-malarial treatment
Trial: 25429720
Drug: Remifentanil (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.15 μg(‐1)kgIBW(‐1) min(‐1))
Trial: 25429720
Drug: Fentanyl (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (200 to 500 μg as needed)
Trial: 8472828
Drug: (+/‐)‐telenzepine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+/‐)‐telenzepine (3 mg orally at 6 p.m. for 5 days)
Trial: 27385377
Drug: Foley's catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley's catheter or low-dose vaginal misoprostol alone
Trial: 24932625
Drug: intralymphatic immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intralymphatic immunotherapy (ILIT)
Trial: 24932625
Drug: subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous immunotherapy (SCIT)
Trial: 17652881
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of non-expanded peripheral blood mononuclear cells (PBMNCs) within 5 days after PCI
Trial: 17652881
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of PBMNCs
Trial: 15704689
Drug: Vardenafil, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil, a phosphodiesterase 5 inhibitor; dosage and duration not specified.
Trial: 12015188
Drug: Telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg (titrated to 80 mg after 4 weeks)
Trial: 12015188
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg (titrated to 20 mg after 4 weeks)
Trial: 12015188
Drug: Telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg / Enalapril 10 mg
Trial: 10369630
Drug: Alternate-day omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alternate-day omeprazole therapy
Trial: 10369630
Drug: On-demand therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand therapy with omeprazole
Trial: 7594361
Drug: Ease of
RxNorm normalized name: BOIL-EASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ease of administration of BMSE
Trial: 389354
Drug: Clotrimazole (local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole (local treatment for 6 days)
Trial: 389354
Drug: Clotrimazole (local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole (local treatment for 6 days) + Nystatin (oral treatment for 10 days)
Trial: 25801708
Drug: EADB-100 (Quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EADB-100 (Quadruple therapy with esomeprazole, amoxicillin, DOX-100 mg b.i.d., and bismuth subcitrate)
Trial: 25801708
Drug: EADB-200 (Quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EADB-200 (Quadruple therapy with esomeprazole, amoxicillin, DOX-200 mg b.i.d., and bismuth subcitrate)
Trial: 23600548
Drug: 300IR 5-grass
RxNorm normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300IR 5-grass pollen sublingual tablet (4M group)
Trial: 23600548
Drug: 300IR 5-grass
RxNorm normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300IR 5-grass pollen sublingual tablet (2M group)
Trial: 12641501
Drug: Conventional 13C-UBT
RxNorm normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Conventional 13C-UBT (75 mg 13C-urea)
Trial: 12641501
Drug: Tablet-based 13C-UBT
RxNorm normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet-based 13C-UBT (100 mg 13C-urea)
Trial: 12641501
Drug: Tablet-based 13C-UBT
RxNorm normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet-based 13C-UBT (50 mg 13C-urea)
Trial: 12641501
Drug: Conventional 13C-UBT
RxNorm normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Conventional 13C-UBT (75 mg 13C-urea) at follow-up
Trial: 12641501
Drug: Tablet-based 13C-UBT
RxNorm normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet-based 13C-UBT (100 mg 13C-urea) at follow-up
Trial: 12641501
Drug: Tablet-based 13C-UBT
RxNorm normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet-based 13C-UBT (50 mg 13C-urea) at follow-up
Trial: 8478759
Drug: Midazolam (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.35 mg/kg)
Trial: 8478759
Drug: Diazepam (0.70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.70 mg/kg)
Trial: 3094356
Drug: Sustained-release nitroglycerin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release nitroglycerin, 13 mg
Trial: 3094356
Drug: Diltiazem, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem, 60 mg
Trial: 26945843
Drug: IL-1 receptor
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-1 receptor antagonist (IL-1Ra)
Trial: 23335852
Drug: Calcium dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesilate (CaD) 500 mg daily for 3 months
Trial: 20358358
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg IV zoledronic acid
Trial: 16636210
Drug: Warfarin sodium
RxNorm normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin sodium (target international normalized ratio, 2.0‐3.0)
Trial: 11226087
Drug: RSR13 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSR13 (75 mg/kg and 100 mg/kg doses)
Trial: 11226087
Drug: RSR13 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSR13 (all doses)
Trial: 3258222
Drug: Acute normovolemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute normovolemic hemodilution (10 ml/kg; n = 15) using hydroxyethyl starch solution (HES)
Trial: 25778112
Drug: Concurrent presence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent presence of low VM area, high VM %Fat, and high BMI
Trial: 23177418
Drug: Split-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose group (75 IU rHLH given as four equally divided doses)
Trial: 23177418
Drug: Single-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose group (75 IU rHLH given as a single dose)
Trial: 23177418
Drug: Split-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose group
Trial: 19657112
Drug: Higher plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher plasma levels of sex hormone-binding globulin (SHBG)
Trial: 19657112
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in plasma level of sex hormone-binding globulin (SHBG)
Trial: 16920503
Drug: Preoperative recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative recombinant human GM-CSF (rhGM-CSF) administration
Trial: 11383355
Drug: 2 implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 implants with ball attachment
Trial: 11383355
Drug: 2 implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 implants interconnected with a bar
Trial: 11383355
Drug: 4 implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 implants interconnected with bars
Trial: 8996264
Drug: 5-fluorouracil/epinephrine injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil/epinephrine injectable gel (5-FU/epi gel)
Trial: 8996264
Drug: 5-fluorouracil/epinephrine injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil/epinephrine injectable gel (5-FU/epi gel) at a dose of 0.5 ml three times a week for 2 weeks
Trial: 30477846
Drug: Disease-specific suggestions
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-specific suggestions (using counter-hyperarousal hypnotic exercise and screen visualization technique)
Trial: 25909533
Drug: Implant-connected partial
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-connected partial dentures
Trial: 16622463
Drug: Dose-dense chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense chemotherapy (DD) with epirubicin 90 mg/m² plus paclitaxel 175 mg/m² in four 14-day cycles, followed by CMF 600/40/600 in three 14-day cycles, plus filgrastim 5 µg/kg/day
Trial: 16622463
Drug: Conventional-schedule chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-schedule chemotherapy (CS) with epirubicin 90 mg/m² plus cyclophosphamide 600 mg/m² in four 21-day cycles, followed by CMF 600/40/600 in three 21-day cycles, plus filgrastim if required
Trial: 10195613
Drug: Yellow fever
RxNorm normalized name: yellow fever live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow fever vaccine administered 1-6 days after measles vaccination
Trial: 10195613
Drug: Yellow fever
RxNorm normalized name: yellow fever live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow fever vaccine administered 7-13 days after measles vaccination
Trial: 10195613
Drug: Yellow fever
RxNorm normalized name: yellow fever live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow fever vaccine administered 14-21 days after measles vaccination
Trial: 10195613
Drug: Yellow fever
RxNorm normalized name: yellow fever live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow fever vaccine administered 22-27 days after measles vaccination
Trial: 10195613
Drug: Yellow fever
RxNorm normalized name: yellow fever live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow fever vaccine administered >28 days after measles vaccination
Trial: 1962905
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (FR‐860)
Trial: 1962905
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (H‐25)
Trial: 1962905
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (F‐50)
Trial: 1962905
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (F‐25 and F‐35)
Trial: 29625777
Drug: Pulmonary Rehabilitation
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary Rehabilitation (PR) thrice weekly for 12 weeks
Trial: 29625777
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi five times weekly for 12 weeks
Trial: 26302142
Drug: 6-month pharmacist
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month pharmacist intervention comprising collaborative care, medication review, and tailored adherence counseling including motivational interviewing and telephone follow-ups.
Trial: 23208945
Drug: Classification-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classification-based cognitive functional therapy
Trial: 18192510
Drug: High-dose senicapoc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose senicapoc (10 mg/day)
Trial: 10568568
Drug: Nitric-oxide-generating gel
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric-oxide-generating gel
Trial: 10568568
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (KY jelly only)
Trial: 7061569
Drug: Patients after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients after chemotherapy
Trial: 30835326
Drug: Non-RA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-RA treatment
Trial: 29089056
Drug: Lotilaner (20-43
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotilaner (20-43 mg/kg)
Trial: 26227783
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg synthetic GABA
Trial: 26227783
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg oral microcrystalline cellulose (placebo)